As GlaxoSmithKline plc Nears A 52-Week Low, Is It Time To Buy?

Is now the time to buy GlaxoSmithKline plc (LON: GSK) or should you stay away?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2015 is shaping up to be a pretty terrible year for GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). Year to date, the company’s shares have hardly budged while the rest of the FTSE All World Pharma & Biotech sector has risen by 10%. 

And now Glaxo’s shares are closing in on their 52-week low of 1,296p, after falling by 14% during the past 12 months.

But should investors look to buy on this weakness or could Glaxo’s shares fall further? 

Should you invest £1,000 in Polymetal right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Polymetal made the list?

See the 6 stocks

Investor concern 

Investors have turned their back on Glaxo during the past 12 months for several reasons.

Firstly, there’s been plenty of speculation that the company is contemplating a dividend cut. As a result, investors have been selling up and searching for a safer yield elsewhere. 

Secondly, there’s been some concern about Glaxo’s new business strategy. In particular, the group has recently reduced its dependence on the lucrative pharmaceutical market by increasing investment in the slow-and-steady vaccines and consumer healthcare market.

For example, a $20bn asset swap with Novartis last year saw Glaxo trade its lucrative cancer drug portfolio for vaccines and consumer healthcare assets.

Management targets

Investors’ concerns regarding Glaxo’s change of strategy and dividend sustainability are well founded.

However, the company’s management has recently come out to dispel these worries. 

It’s expected that Glaxo’s core earnings per share will decline by 15% this year. But from 2016 to 2020, group revenue is expected to grow at a compound annual growth rate of “low-to-mid single digits”. What’s more, over the same period, core earnings per share are expected to expand at a rate in the “mid-to-high single digits”.

Cost savings will help the group maintain its dividend payout. Glaxo’s management has stated that a per-share payout of at least 80p is guaranteed for the next three years. 

At present levels, a payout of 80p per share translates into a dividend yield of 5.9%. 

Impressive pipeline 

Concerns over Glaxo’s business strategy also seem to be overdone. Glaxo has had more drugs approved by regulators than any other pharmaceutical company over the last five years. And this trend is set to continue. 

City analysts who specialise in the pharmaceutical sector have commended Glaxo’s treatment pipeline, rating it as one of the best in the business. Glaxo’s R&D spending currently amounts to £3.5bn per annum. 

Also, Glaxo is hunting out the best joint-venture opportunities in the market.

This week the company announced the launch of three early-stage biotech companies jointly funded with Avalon Ventures, a US investment firm. 

The bottom line 

Overall, Glaxo looks to be a classic contrarian buy after recent declines.

The company’s dividend appears to be safe for the next three years, and while earnings are set to contract this year, steady growth is predicted through to the end of the decade.

For long-term investors who are prepared to wait, and take home an attractive 5.9% dividend yield, Glaxo could be a great buy. 

Should you buy Polymetal now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

The dividend yield on this FTSE 100 stock has jumped 50% in a year. Time to buy?

Jon Smith explains why the yield on a FTSE 100 share has risen sharply over the past year but details…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

AstraZeneca’s share price is down 20% from September, so is it time for me to buy?

AstraZeneca’s share price has fallen a long way this year, which could mean a bargain to be had, so I…

Read more »

Man smiling and working on laptop
Investing Articles

2 top gold ETFs to consider in May!

Buying a gold exchange traded fund this month is a great idea to consider as the precious metal targets new…

Read more »

Middle aged businesswoman using laptop while working from home
Investing Articles

3 dirt cheap FTSE 250 shares for May

I think these FTSE 250 shares could be among the London stock market's best bargains to consider following recent turbulence.

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

£500 to invest in an ISA each month? Here’s how to target a potential £60k+ second income!

A regular monthly investment in a Stocks and Shares ISA could build a huge passive income in retirement. Let me…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

£10,000 invested in Jet2 shares 1 year ago is now worth…

Jet2 shares jumped on Tuesday 29 April after a positive trading report boosted investor sentiment. Dr James Fox explores his…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

£10,000 invested in BT shares 5 years ago is now worth…

BT shares have shone over the past 12 months, and that’s a little painful for me to say, having touted…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

I think this could be the best investment opportunity on the FTSE 100

Like many FTSE 100 stocks, this one has been through the mill in 2025. However, it hasn’t recovered, potentially offering…

Read more »